Worldwide Research and Development
Welcome to Pfizer Worldwide Research & Development (WRD), where strategic partnership is a mission of our effort to deliver important medicines and vaccines to people in need across the globe.
As the world's leading biopharmaceutical company, Pfizer is proud to offer you access to our world-class research scientists, our global network of external research collaborations, and our industry-leading manufacturing and commercial capabilities.
Combining your science, tools and technologies with Pfizer's expertise in small molecule and biologic design and development could hold the key to breakthrough therapies for patients worldwide.
We are eager to explore the possibilities of partnership and invite you to closely review this website.
Cardiovascular & Metabolic Diseases
The current projections for growth in the prevalence of diabetes threaten to create a global public health crisis. WHO predicts that the worldwide prevalence of diabetes will grow from 171 million in 2000 to 373 million by 2030.
Pfizer is a global leader in developing medicines for patients suffering from chronic immune diseases.
Inflammation & Remodeling
The Inflammation & Remodeling research unit's goal is to discover and develop novel and differentiated therapeutic options targeting chronic inflammatory diseases.
In the US today, 7 of the 10 leading causes of disability are neurological and psychiatric disorders. To meet these patient needs, Pfizer is taking a bold leadership approach that will evolve from dealing with symptoms to modifying diseases, where scientifically feasible.
Pfizer's Oncology Research Unit (ORU) strives to advance the frontiers of cancer biology and to translate this knowledge into high-impact medicines for cancer patients. The ORU comprises four pillars: Tumor Cell Biology; Bioconjugates Discovery and Development; Precision Medicine; and Integrative Biology and Biochemistry.
Pain & Sensory Disorders
Pfizer is a global leader in pain medicines with products in each of the major classes: Celebrex® (celecoxib; COX2 inhibitor), Lyrica® (pregabalin) and Neurontin® (gabapentin; α2δ ligands), Avinza® (morphine sulphate), and Oxecta® (oxycodone immediate release, opioid agonists).
Pfizer's Rare Disease Research Unit (RDRU) is adopting an innovative and collaborative approach to the development of new medicines whereby it looks to develop strategic partnerships with academic and commercial enterprises to create novel therapeutics across the spectrum of rare diseases.
Our vision is to become a recognized leader in the development of prophylactic and therapeutic vaccines for unmet medical needs at all stages of life and for all geographies.
Biologics Product & Process Development
WRD Pharmaceutical Sciences envisions a network of strategic partnerships integral to its biologics technology initiatives, which include biopharmaceutical and vaccine development and manufacturing and prokaryotic expression to augment core competencies.
Pfizer strives to become the leading biotherapeutics company by building on internal expertise and fostering strategic partnerships to access the best technologies with patent protection and technical capabilities that provide a competitive advantage.
Pfizer's Drug Safety R&D group develops and applies the skills, experience and scientific tools necessary for safety assessment and risk management of targets and compounds across the research, development and commercial phases of drug development.
Modification of epigenetic signaling has the potential to serve as a new route in to the treatment of human diseases, including a range of chronic and life-threatening conditions. Epigenomic profiling may form a component of successful Precision Medicine strategies, for conditions with epigenetic and non-epigenetic treatments.
Pharmacokinetics, Dynamics & Metabolism (PDM)
PDM is focused on the development of innovative small and large molecule therapies through an improved understanding of targets, pathways and modeling for preclinical efficacy, discrete toxicity, and safety biomarkers.
Precision Medicine is an approach to discovering and developing medicines and vaccines that deliver superior outcomes for patients, by integrating clinical and molecular information to understand the biological basis of disease.
Rinat was acquired by Pfizer in 2006 and is operated as an independent biotechnology unit within Pfizer's Worldwide R&D group. Rinat focuses on antibody-based therapeutics across all disease areas of interest to Pfizer.
Small Molecule Product & Process Development
WRD Pharmaceutical Sciences envisions a network of partners to enhance active pharmaceutical ingredients (API) and drug product development and manufacturing of small molecules.
Small Molecule Therapeutics Discovery
Pfizer's Worldwide Medicinal Chemistry core capabilities include small molecule design and associated functions including structural biology and computational chemistry, synthetic innovation and compound safety prediction.
Innovative Partnering Models
Pfizer has established a number of novel approaches to work with partners in developing new medicines. Moving beyond traditional collaborations and licensing deals.